Contralateral Risk-Reducing Mastectomy: Review of Risk Factors and Risk-Reducing Strategies

Table 2

Risk reduction of CBC associated with chemoprevention and surgery.

	Risk reduction; (95% CI)
Chemoprevention
Antiendocrine
Tamoxifen in BRCA1/2 mutation carriers	OR 0.5 (0.3–0.9)
Tamoxifen in noncarriers	50% risk reduction
Aromatase inhibitors in noncarriers	70% risk reduction
Chemotherapy
Chemo versus no chemo	RR 0.6 (0.4–0.8)
Surgery	20-year survival benefit
CRRM
CRRM in BRCA1/2 mutation carriers	14.9%
CRRM in nonmutation carriers	<1%